Medpace CEO Troendle Sells $10 Million in Stock

The Motley Fool··US·Read original
2▲0 ▼1Impact / 5
Summary · why it matters

Medpace Holdings CEO August J. Troendle sold 15,978 shares of common stock in a transaction valued at $10.0 million, according to an SEC Form 4 filing. The sale was executed at weighted average prices between $620.00 and $628.68 per share, following a limit order placed during an open trading window. After the sale, Troendle retains a combined direct and indirect position valued at $3.27 billion, representing 19% of the company's total market capitalization. The majority of his holdings, approximately 4.7 million shares, are held through Medpace Investors, LLC, where he serves as sole manager and controlling unit holder. Medpace shares have delivered a 34% one-year total return, with TTM revenue of $2.8 billion and net income of $491.5 million.

Impact on assets 1

Biotech & Genomic Medicine▼ · 1 stocks
© 2026 MarketIVNews